| Objective: To evaluate the safety and efficacy of intravitreal injection of Conbercept combined with laser in the treatment of branched retinal vein occlusion(BRVO)secondary macular edema(ME).To compare and analyze the different therapeutic effects of conbercept single injection in the treatment of BRVO secondary ME.Methods: 40 patients(eyes)with BRVO secondary ME treated in our hospital were randomly divided into two groups,20 patients(eyes)per group;one group was treated by the intravitreal conbercept injection(IVC group),another group was applied by a combination of conbercept injection and local in the disseminated laser treatment(COM group),both groups were treated with 1+ pro re nata(PRN).The COM group was treated with local retinal dispersive laser treatment one or two week after the first injection.Follow-up and record the best corrected visual acuity(BCVA),intraocular pressure(IOP),central macular thickness(CMT)before and 1 week,1,2,3 and 6 months after treatment.The number of injections and adverse events at each follow-up were recorded.Results: 1.The baseline CMT of the IVC group was 523.35 ± 199.86?m,the average CMT of different time points(1 week,1,2,3,and 6 months)after treatment were: 361.45 ± 108.30?m,338.30 ± 81.26?m,275.60 ± 43.30?m,257.25 ± 49.62?m,265.10 ± 82.04?m,the difference was statistically significant compared with that before treatment(P <0.001).2.The baseline CMT of the COM group was 528.55 ± 244.41?m,the average CMT of different time points(1 week,1,2,3,and 6 months)after treatment were 372.60 ± 116.27?m,312.05 ± 84.84?m,263.60 ± 59.67?m,250.25 ± 53.45?m,256.15 ± 72.68?m,the difference was statistically significant compared with that before treatment(P <0.001).3.The baseline BCVA(Log MAR)of the IVC group was 0.78 ± 0.35,the average BCVA(Log MAR)of different time points(1 week,1,2,3,and 6 months)after treatment were: 0.53 ± 0.33,0.46 ± 0.20,0.38 ± 0.18,0.36 ± 0.26,0.38 ± 0.23,the difference was statistically significant compared with before treatment(P = 0.003 at 1 week,P(27)0.001 at all other time points).4.The baseline BCVA(Log MAR)of the COM group was 0.80 ± 0.39,the average BCVA(Log MAR)of different time points(1 week,1,2,3,and 6 months)after treatment were: 0.55 ± 0.34,0.43 ± 0.29,0.35 ± 0.26,0.32 ± 0.27,0.34 ± 0.29,the difference was statistically significant compared with before treatment(P = 0.01 at 1 week,P(27)0.001 at all other time points).5.There was no significant difference between the IVC group and the COM group in the same time period of BCVA(Log MAR)value and CMT value(P > 0.05).6.The average number of injections in the IVC group was 3.10 ± 0.79,and the average number of injections in the COM group was 2.85 ± 0.88.There was no significant difference between the two groups(P = 0.392).7.No serious ocular adverse reactions and systemic complications such as retinal detachment,endophthalmitis,vitreous hemorrhage and neovascular glaucoma occurred during the treatment.Conclusion: 1.Intravitreal injection of conbercept combined with laser treatment of BRVO secondary ME is safe and effective in improving visual function and reducing macular edema.2.Intravitreal injection of conbercept in the treatment of BRVO secondary ME is safe and effective in improving visual function and reducing macular edema.3.Comparing the combination therapy with the injection alone has the same therapeutic effect;the combination therapy does not reduce the need for reinjection. |
PDF Full Text Request